Cytidine

also known as CYT · MMV638723 · NSC-20258

Developed for: bipolar disorder · bipolar depression
Investigated by: Fundação Educacional Serra dos Órgãos · Mclean Hospital · Stanley Medical Research Institute

today NCT02640417 · Ph 4 NCT00854737 · Ph 2

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial
Phase 2	NCT00854737	Jul 2004 → Aug 2007	bipolar disorder	Mclean Hospital	Completed	No outcome recorded
Phase 41 trial
Phase 4	NCT02640417	Mar 2016 → Mar 2018	—	Fundação Educacional Serra dos Órgãos	Completed	No outcome recorded

Also used as a comparator or background therapy in 1 trial

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT01543139 Comparator	Dec 2015 → Apr 2017	bipolar depression	Ewha Womans University	Withdrawn	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	Cytidine	“cytidine (2g po daily for 4 months)” NCT00854737 ↗ 2 NCT02640417 ↗ NCT01543139 ↗
Known as	CYT	“oral cytidine (CYT), a pyrimidine with reported preclinical and clinical antidepressant-like effects” PMID 22926607 ↗ Oct 2012
Known as	MMV638723	ChEMBL registry synonym — accepted as the source's own label CHEMBL95606 ↗
Known as	NSC-20258	ChEMBL registry synonym — accepted as the source's own label CHEMBL95606 ↗
Modality	Small molecule	— CHEMBL95606 ↗
Route	Oral	“cytidine (2g po daily for 4 months)” NCT00854737 ↗